

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently Amended): A pharmaceutical composition for preventing and treating dementia or impairment of learning and memory and cognitive function in a patient in need thereof, which contains minocycline as an active ingredient to inhibit brain cell toxicity of C-terminal protein.

Claims 2 - 20. (Canceled)

21. (New) A method for treating dementia in a patient, comprising administering a therapeutically effective amount of minocycline to a patient in need thereof to inhibit brain cell toxicity of C-terminal protein.

22. (New) The method according to claim 21, wherein the minocycline is included in a composition containing the minocycline as an active ingredient.

23. (New) The method according to claim 21, wherein the dementia comprises Alzheimer's disease.

24. (New) The method according to claim 22, wherein the dementia comprises Alzheimer's disease.

25. (New) The method according to claim 22, wherein the minocycline is administered intravenously.

P24188.A04

26. (New) The method according to claim 22, wherein the minocycline is administered intramuscularly.

27. (New) The method according to claim 22, wherein the minocycline is administered orally.

28. (New) A method for treating memory impairment in a patient, comprising administering a therapeutically effective amount of minocycline to a patient in need thereof to inhibit brain cell toxicity of C-terminal protein.

29. (New) The method according to claim 28, wherein the minocycline is included in a composition containing the minocycline as an active ingredient.

30. (New) The method according to claim 29, wherein the minocycline is administered intravenously.

31. (New) The method according to claim 29, wherein the minocycline is administered intramuscularly.

32. (New) The method according to claim 29, wherein the minocycline is administered orally.